Phase 2 UNITY-NHL Study Regarding Umbralisib
Apr 15, 2021 ·
2m 31s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.
Information
| Author | Peter Ciszewski, CheckRare |
| Organization | CheckRare |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Comments